Contribute Try STAT+ Today

It seemed a foregone conclusion: Despite the early popularity of companies offering health and ancestry insights for the cost of roughly $200 — and the brief but awkward experience of spitting into a tube — the consumer genetics industry was not going to thrive. Privacy concerns took center stage. Sales declined. Profits never materialized.

But on Thursday, 23andMe threw water on that premise by filing paperwork with the Securities and Exchange Commission to go public, providing a glimpse into the financials of its business.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.